Week in Review: Lifestyle Scientific to Form Pacemaker Partnership with Medtronic

Lifetech Scientific of China and Medtronic, both medical device companies, agreed to develop pacemaker and cardiac lead products for the China market using Medtronic’s technology; Gilead Sciences will allow China drugmakers to develop generic versions of a new HIV/HBV treatment that is currently in a Phase III trial; Hangzhou Tigermed, a CRO, completed its $50 million acquisition of a 70% stake in US-based Frontage Labs; Fosun Pharma acquired 37% of Germany’s miacom diagnostics and will market miacom’s  diagnostic assays in China and Asia; Cold Genesys of California raised $13.8 million from Ally Bridge, a Hong Kong-US life science investing firm; CANbridge Life Sciences of Beijing in-licensed China rights to an oral mucositis treatment from EUSA Pharma; Sotio, a Czech biotech, opened a Beijing lab from which it will produce DCVAC, the company’s autologous cellular immunotherapy for cancer; and SGS Life Science Services, a Swiss company that offers contract research and analytical lab services, expanded its Shanghai lab to meet demand. More details…. Stock Symbols: (HK: 1302) (NYSE: MDT) (NSDQ: GILD) (SHE: 300347) (SHA: 600196; HK: 2196) Share this with colleagues: // //